Charles River announced today that it has completed the previously announced acquisition of Citoxlab.
Citoxlab is a premier, non-clinical contract research organization (CRO), specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing. With operations in Europe and North America, the acquisition of Citoxlab will further strengthen Charles River’s position as the leading, global, early-stage CRO by expanding its scientific portfolio and geographic footprint, which will enhance our ability to partner with clients across the drug discovery and development continuum.
Citoxlab provides a broad suite of early-stage services that would strengthen Charles River’s existing capabilities in four key areas:
- General and specialty toxicology, including developmental and reproductive toxicology and ocular services, as well as agricultural and industrial chemical testing, including ecotoxicology services
- Preclinical medical device testing services, significantly enhancing Charles River’s existing expertise
- Non-regulated discovery solutions, ranging from traditional DMPK services to drug transporter and drug-to-drug interaction research
- Genomics research, adding unique expertise to Charles River’s capabilities in mechanistic and investigative toxicology
James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, “Citoxlab’s complementary service offering and geographic footprint are an excellent strategic fit and will enable us to enhance the support we can provide for our clients’ early-stage research efforts. The addition of Citoxlab’s talented staff, extensive scientific capabilities, and client-centric approach solidifies our leading position in the outsourced safety assessment market at a time when we believe there is and will continue to be significant client demand for these outsourced services. We are pleased to welcome the exceptional team at Citoxlab to the Charles River family, and look forward to working together to help our clients discover and develop new drugs for the patients who need them.”
Stay connected with us through this exciting transition by joining our new mailing list. Sign up to keep in touch with our industry-leading scientists and receive news about the world-class drug development services and support that our expanded team provides.